CORRECTING and REPLACING Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake

Thu Jun 26, 2014 2:28pm EDT

* Reuters is not responsible for the content in this press release.

CORRECTING and REPLACING Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake

Third paragraph, second sentence has been deleted because of redundancy.

The corrected release reads: 


It is with great sadness that Celgene Corporation (NASDAQ:CELG) announces the death of Rodman L. Drake, a member of its Board of Directors since 2006.

“We are deeply saddened by the passing of Rod Drake,” said Bob Hugin, Chairman and Chief Executive Officer of Celgene Corporation. “Rod was a valued member of our Board and brought a wealth of experience in corporate governance, finance and strategy to Celgene. He contributed to the growth of Celgene and his leadership and friendship will be greatly missed. On behalf of all of our employees and the Board of Directors, I extend our deepest sympathies to his wife, Jackie, and his two sons, Philip and Stephan.”

Mr. Drake served as Chairman of the Company's Management Compensation and Development Committee since June 2007 and was a member of the Nominating, Governance and Compliance Committee since April 2006. Mr. Drake had a long and distinguished career which included serving as CEO and Managing Director of Cresap McCormick and Paget, a leading international management consulting firm; Co-Chairman of KMR Power Company and President of the Mandrake Group, a consulting firm specializing in strategy and organizational design. Most recently, Mr. Drake served as the Managing Director of Baringo Capital, LLC, a private equity group he co-founded. Mr. Drake received an MBA from Harvard Business School and a bachelor’s degree from Yale.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit Follow us on Twitter @Celgene as well.

Celgene Corporation
Brian Gill, 908-673-9530
VP, Corporate Communications
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.